Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Open access

Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy

George Merhej Gurusankar Ramamoorthy Danda Chapagai Mohammad Esfini Farahani Yifan Kong C. N. Rao Jessy M. Stafford Zachary T Mack Cassidy E Socia Shikha Kumari Kristen Hogan Niti Jani Marie Pena Elmar Nurmemmedov Ivan Babic Mengqian Chen Xiaoqi Liu Michael D. Wyatt Campbell McInnes
Jul 2026 · bioRxiv · 0 citations · 42 references
Medicine Biology

TL;DR

These studies establish selective inhibition of the PLK1 Polo-box domain as a viable therapeutic strategy, provide in vivo proof-of-concept for the REPLACE approach, and identify abbapolins as promising leads for advanced prostate cancer.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Jul 2026

Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors

Beyond enabling the discovery of several new potent and selective small molecules, these studies have allowed us to elucidate key parameters for potency, selectivity, and metabolic stability that should aid future efforts in RBP drug discovery.

G. M. Scherer, Jacob P. Sorrentino, A. K. Jaiswal et al. · 0 citations
Open access Aug 2026

Preclinical Evaluation of Combined Polo-like Kinase 1 Inhibition and Navitoclax in Experimental Models of Lung Cancer

While PLK-1 inhibition exerts antitumor effects in certain in vivo contexts, the therapeutic synergy observed in vitro with Navitoclax does not consistently translate to in vivo lung cancer models, which highlights the challenges of translating combinatorial mitotic and apoptotic targeting strategies into effective in...

Bárbara Pinto, Mateus Prates-Rodrigues, D. A. B. Nobre et al. · 0 citations
Open access Jul 2026

Dual-Target Inhibition of CDK5 and PBK in Pituitary Neuroendocrine Tumors: Mechanisms and Therapeutic Potential

The CDK5-PBK mutual phosphorylation axis serves as a key driver of invasiveness in PitNETs and proguanil hydrochloride represents a promising candidate dual-target therapeutic agent capable of disrupting this pathway to suppress tumor growth.

Jinghao Jin, Zhaoyi Yi, Hong-Yun Wang et al. · 0 citations
Review Jul 2026

Targeting p21-activated kinase 4: Recent advances in the discovery of PAK4 inhibitors and strategies for isoform selectivity.

p21-activated kinase 4 (PAK4), a Group II PAK family member, is a therapeutically relevant candidate target in cancer, metabolic disease, and tissue injury. However, translation of PAK4 biology into drug candidates has been constrained by the conserved ATP-binding architecture of PAK isoforms, unfavorable pharmacokinet...

Rui-Qing Shi, Xue Feng, Zixu Wang et al. · 0 citations
Open access Jul 2026

Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy

The authors design and characterise FR-027, a reversible covalent inhibitor of XPO1 that does not induce XPO1 degradation, demonstrating strong antitumour activity, including in brain tumours, with an improved safety profile in mice.

Janne Van Hauwenhuyse, F. Reniers, L. Persoons et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.